Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Apr 28, 2026 · 10-Q · 28 days after period end · 0001808805-26-000022
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$14.70M | -$16.61M | -$18.73M | -$14.97M |
| EPS Diluted | -$0.12 | -$0.13 | -$0.15 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed Apr 28, 2026 · 28 d after period end
